11-04 :: April/May 2011
nanotimes
Companies Facts
compared with $25.4 million for the same period in 2010. III-V revenue increased 21% to $17.6 million from $14.5 million for the comparable quarter last year, reflecting stronger first quarter orders from the Company’s integrated circuit partners. Display reve- nue grew 59% to $17.3 million versus $10.9 million in the first quarter of 2010, primarily as a result of higher military display sales.
Net income for the first quarter of 2011 was $2.1 million, or $0.03 per diluted share, compared with $1.0 million, or $0.02 per diluted share, for the 2010 first quarter. Included in the 2010 results of opera- tions was approximately $373,000 from the receipt of insurance proceeds and $686,000 from the sale of Micrel stock. Gross margin for the first quarter of 2011 increased to 33.3% of product revenues from 26.5% of product revenues for the same period of 2010, reflecting an increase in sales of military dis- plays and leveraging the III-V fixed costs over greater volume. R&D expense increased to $6.4 million, or 18.3% of revenues in 2011, compared with $4.3 million, or 16.9% of revenues in 2010, as a result of the Company’s investments in the Golden-i product, III-V products for smartphones and the acquisition of Forth Dimension Displays Ltd. (FDD).
http://www.kopin.com
K
romax will represent Alchimer’s total through- silicon via (TSV) solution in Taiwan, including
its Electrografting (eG) wet deposition technology. Electrografting is Alchimer’s breakthrough electroche- mical process that enables the growth of extremely high-quality nanometric films for TSVs, semiconduc- tor interconnects, MEMS and other electronic appli- cations.
“This is further recognition in one of the most impor- tant chip-producing markets that Alchimer’s mature technology is recognized as a cost-effective solution for high aspect ratio TSVs, and we are pleased to announce this expansion of sales and service for our Taiwanese customers,” said Steve Lerner, Alchimer CEO.
“Kromax’s history of operations in Taiwan and the rest of Asia, its strong relationships with Alchimer’s customers, and its excellentreputation for bringing breakthrough technologies to the market make it a very good fit for Alchimer.”
http://www.kromax.com
http://www.alchimer.com P
roBioGen AG and Life Technologies Corporation announced the launch of the new Freedom™
CHO-S™ Kit as the result of a successful co-deve- lopment. The kit was built for developing stable high yield production cell lines in less than 4 months, and is based on Life Technologies’ CHO-S™ Cells. The Freedom™ CHO-S™ Kit platform enables end-users the cost- and time-efficient creation of stable cell lines for research and commercial purposes. The kit’s applicability and efficiency was confirmed in several studies, in which antibody titers of 1 to 3 g/L have been obtained.
http://www.probiogen.de
http://www.lifetechnologies.com L
una Innovations Incorporated (NASDAQ: LUNA) has agreed with Intuitive Surgical, Inc. (NAS-
DAQ: ISRG), to extend its development efforts under its development and supply agreement with Intuitive
33
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93